Congenica

Company profile

About Congenica

Congenica is a clinical genomics company that transforms raw sequencing data into actionable clinical insights for precision medicine. Founded at the Wellcome Sanger Institute in 2012, Congenica has been at the heart of the UK's genomic medicine journey for over a decade, from the 100,000 Genomes Project to today's NHS Genomic Laboratory Hubs (GLHs). In 2025, Congenica joined SeqOne to create a global leader in AI-powered genomic medicine. The company's platform provides advanced NGS analysis across rare diseases, oncology, and infectious diseases, combining AI-driven variant prioritization with clinical-grade accuracy. Their DiagAI technology automatically identifies 96% of diagnostic variants with 92% specificity, ranking 90% of causal variants in the top 3 positions. The platform includes comprehensive capabilities for panels, whole exome sequencing (WES), and whole genome sequencing (WGS), with multi-caller architecture, CNV/SV detection, mitochondrial analysis, and automated ACMG classification. Congenica serves health systems, diagnostic laboratories, and genomic medicine services worldwide, with particular strength in the UK's NHS where they support multiple Genomic Laboratory Hubs. The company also provides Clinical Interpretation Services through NHS-trained genomic experts who deliver variant analysis and clinical reporting. As part of the SeqOne family, Congenica now operates with a 125+ person team across Cambridge, Paris, and Montpellier, backed by €20M in recent funding and serving 190+ laboratories in 35+ countries.

Company description · Congenica official website

Mission. Genomic Medicine for Everyone. We believe every patient deserves the benefit of genomic medicine, regardless of geography or healthcare system.